Last reviewed · How we verify
SG001
SG001 is a small molecule drug that targets the SGLT2 receptor.
SG001 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | SG001 |
|---|---|
| Also known as | Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, Recombinant Human Anti-PD-1 Monoclonal Antibody |
| Sponsor | Shanghai JMT-Bio Inc. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, SG001 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
Key clinical trials
- A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. (PHASE2, PHASE3)
- Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R) (PHASE2)
- SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC (PHASE2)
- Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors. (PHASE1, PHASE2)
- An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis (EARLY_PHASE1)
- Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer (PHASE2)
- A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma. (PHASE1, PHASE2)
- A Study of Simmitinib Plus SG001 in Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SG001 CI brief — competitive landscape report
- SG001 updates RSS · CI watch RSS
- Shanghai JMT-Bio Inc. portfolio CI